This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gikas, A.
Right arrow Articles by Tselentis, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gikas, A.
Right arrow Articles by Tselentis, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2001, p. 3644-3646, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3644-3646.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Newer Macrolides as Empiric Treatment for Acute Q Fever Infection

Achilleas Gikas,* Diamantis P. Kofteridis, Andreas Manios, John Pediaditis, and Yiannis Tselentis

Zoonoses and Clinical Bacteriology, Parasitology, Geographical Medicine, and Department of Internal Medicine, University Hospital of Heraklion, Heraklion, Greece

Received 3 November 2000/Returned for modification 27 June 2001/Accepted 19 September 2001

The effectiveness of newer macrolides in acute Q fever for 113 patients was recorded. The mean times to defervescence were 2.9 days for doxycycline and 3.3, 3.9, 3.9, and 6.4 days for clarithromycin, roxithromycin, erythromycin, and beta -lactams, respectively (P < 0.01 for macrolides versus beta -lactams). We conclude that macrolides may be an adequate empirical antibiotic therapy for acute Q fever.

* Corresponding author. Mailing address: Clinical Bacteriology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of Heraklion, Heraklion, 1352/71110 Crete, Greece. Phone: 30-81-392 360. Fax: 30-81-392 847. E-mail: gikas{at}med.uoc.gr.

Antimicrobial Agents and Chemotherapy, December 2001, p. 3644-3646, Vol. 45, No. 12
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.12.3644-3646.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hartzell, J. D., Wood-Morris, R. N., Martinez, L. J., Trotta, R. F. (2008). Q Fever: Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 83: 574-579 [Abstract] [Full Text]  
  • Woc-Colburn, A. M., Garner, M. M., Bradway, D., West, G., D'Agostino, J., Trupkiewicz, J., Barr, B., Anderson, S. E., Rurangirwa, F. R., Nordhausen, R. W. (2008). Fatal Coxiellosis in Swainson's Blue Mountain Rainbow Lorikeets (Trichoglossus haematodus moluccanus). Vet Pathol 45: 247-254 [Abstract] [Full Text]  
  • MOROVIC, M. (2005). Q FEVER PNEUMONIA: ARE CLARITHROMYCIN AND MOXIFLOXACIN ALTERNATIVE TREATMENTS ONLY?. Am J Trop Med Hyg 73: 947-948 [Abstract] [Full Text]  
  • Brennan, R. E., Samuel, J. E. (2003). Evaluation of Coxiella burnetii Antibiotic Susceptibilities by Real-Time PCR Assay. J. Clin. Microbiol. 41: 1869-1874 [Abstract] [Full Text]  
  • Raoult, D. (2003). Use of Macrolides for Q Fever. Antimicrob. Agents Chemother. 47: 446-446 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»